Effects of VIIa-mediated thrombin generation on platelet adhesion to PMA-ECM in the presence of αIIbβ3-blocking drugs
| Additions . | Surface coverage, % ± SEM . |
|---|---|
| Abciximab | 5.6 ± 1.2 (n = 6) |
| Abciximab + VIIa/X/II | 46.8 ± 1.9* (n = 6) |
| Eptifibatide | 13.0 ± 3.0 (n = 6) |
| Eptifibatide + VIIa/X/II | 46.3 ± 1.0* (n = 6) |
| Tirofiban | 7.9 ± 1.8 (n = 6) |
| Tirofiban + VIIa/X/II | 57.9 ± 1.4* (n = 6) |
| Additions . | Surface coverage, % ± SEM . |
|---|---|
| Abciximab | 5.6 ± 1.2 (n = 6) |
| Abciximab + VIIa/X/II | 46.8 ± 1.9* (n = 6) |
| Eptifibatide | 13.0 ± 3.0 (n = 6) |
| Eptifibatide + VIIa/X/II | 46.3 ± 1.0* (n = 6) |
| Tirofiban | 7.9 ± 1.8 (n = 6) |
| Tirofiban + VIIa/X/II | 57.9 ± 1.4* (n = 6) |
Washed platelets were preincubated with abciximab, eptifibatide, or tirofiban for 30 minutes at room temperature. After addition of washed red cells, platelets were perfused over PMA-ECM for 5 minutes at a shear rate of 1600 s−1; n is the number of evaluated coverslips.
P < .001 versus drug in the absence of VIIa/X/II.